Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baltaleucel-T
- Development stage
- Phase 2
- Lead developer
- Kuur Therapeutics
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Baltaleucel-T is an autologous, cell-based immunotherapy designed to treat cancers associated with Epstein-Barr virus (EBV) infection, including Hodgkin's lymphoma, non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma), nasopharyngeal carcinoma, post-transplant lymphoproliferative disorder (PTLD), and extranodal NK/T-cell lymphoma. The therapy consists of a patient’s own T cells that are isolated and activated ex vivo to recognize multiple EBV antigens—specifically LMP1, LMP2, EBNA1, and BARF1—using dendritic cells presenting these viral proteins. The expanded population of EBV-specific cytotoxic T lymphocytes is then infused back into the patient to target and destroy cancer cells expressing these antigens. Baltaleucel-T was originally developed at Baylor College of Medicine using their proprietary technology platform and has been further developed by Cell Medica (now Kuur Therapeutics), which was acquired by Athenex. The product has received orphan drug designation for certain indications[1][2][3][4][7].
- Brand names
- Cytorex EBV
- Other names
- baltaleucel-T
02
Targets
BARF1 (Epstein-Barr virus BARF1 protein)pMHC (Peptide-MHC complex family)pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus Latent Membrane Protein 2 peptide–Human Leukocyte Antigen complex
Beyond the preview
Go deeper on baltaleucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baltaleucel-T.